Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR
Marketer
Swast Aushadhi Seva Generic Medicine Store
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR
Combifort, a triple-action antidiabetic medication containing glimepiride 1mg, metformin 500mg, and voglibose 0.3mg (extended-release tablets), manages type 2 diabetes in adults by regulating blood glucose. This combined therapy should be ingested with meals, consistently at the same time daily for optimal effectiveness. Dosage is determined individually by your physician and may be adjusted based on your blood sugar response. Continuous use is crucial; discontinuation without medical consultation risks elevated blood sugar, potentially leading to complications like kidney impairment, vision loss, neuropathy, and limb amputation. This medication is a component of a comprehensive diabetes management plan encompassing diet, exercise, and weight management as directed by your healthcare provider. Lifestyle modifications are essential for effective diabetes control. The most prevalent adverse reaction is hypoglycemia (low blood sugar). Learn to recognize its symptoms—sweating, lightheadedness, headache, trembling—and how to counteract it. Regular meals and readily available glucose sources (e.g., sugary foods, fruit juice) are vital preventative measures. Alcohol consumption should be minimized due to its potential to exacerbate hypoglycemia. Other possible side effects include altered taste, nausea, diarrhea, abdominal discomfort, cephalalgia, edema, visual blurring, bone fractures, and upper respiratory infections. Weight gain may occur in some individuals. This medication is contraindicated for patients with type 1 diabetes, diabetic ketoacidosis, or significant liver or kidney dysfunction. Individuals with a history of cardiac disease should inform their physician before commencing treatment, as suitability may be affected. Pregnant or lactating women must consult their doctor prior to use. Regular blood glucose monitoring is necessary, and additional blood tests to track blood cell counts and hepatic function may be recommended by your doctor.
Uses of Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR
Managing type 2 diabetes
Major Benefits of Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR:
Consume this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Extended-Release Tablet should be taken on an empty stomach.
Common Side effects of Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR:
Consume this medication according to your physician's prescribed dosage and schedule. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Extended-Release Tablet should be administered on an empty stomach.
How Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR works:
Glimepiride, metformin, and voglibose (Genericart brand) are combined in a sustained-release tablet (1mg/500mg/0.3mg) to manage diabetes.
SAFETY ADVICE
AlcoholUNSAFE
Consuming alcohol while taking Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg SR tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to a developing fetus. A physician will assess the advantages against possible dangers before prescribing this medication. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The combination medication Glimepiride+Metformin+Voglibose (Genericart brand, 1mg/500mg/0.3mg SR tablet) is likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The combined medication Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg SR tablet is likely unsafe for individuals with kidney impairment and its use should be strictly avoided. Medical advice is crucial. Furthermore, this medication is unsuitable for patients experiencing severe kidney dysfunction.
LiverCAUTION
Patients with liver impairment should use Glimepiride/Metformin/Voglibose 1mg/500mg/0.3mg tablets cautiously, potentially requiring dosage modification. Medical advice is essential. Low initial doses are typically prescribed for those with mild to moderate liver disease; however, this medication is unsuitable for patients with severe hepatic dysfunction.
What if you forget to take Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR :
Should you forget a dose of Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg SR Tablet, ingest it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual medication routine. Avoid taking a double dose.
Facts to Know About Genericart Glimepiride+Metformin+Voglibose 1mg/500mg/0.3mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Type of Therapy | Diabetes Management |
3,018 People bought this recently